1

2 SARS-CoV-2 and endemic coronaviruses: Comparing symptom 3 presentation and severity of symptomatic illness among Nicaraguan 4 Children 5 6 Aaron M Frutos¹, John Kubale¹, Guillermina Kuan², Sergio Ojeda³, Nivea Vydiswaran¹, Nery 7 Sanchez³, Miguel Plazaola³, May Patel¹, Roger Lopez⁴, Angel Balmaseda³, Aubree Gordon^{1*} 8 9 10 ¹ Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, 11 MI, USA ² Health Center Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua 12 ³ Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of 13 14 Health, Managua, Nicaragua. ⁴ Sustainable Sciences Institute, Managua, Nicaragua. 15 16 17 *Corresponding author 18 E-mail: gordonal@umich.edu (AG) 19 ¶ These authors contributed equally. 20

Abstract

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

It has been proposed that as SARS-CoV-2 transitions to endemicity, children will represent the greatest proportion of SARS-Co-V-2 infections as they currently do with endemic coronavirus infections. While SARS-CoV-2 infection severity is low for children, it is unclear if SARS-CoV-2 infections are distinct in symptom presentation, duration, and severity from endemic coronavirus infections in children. We compared symptom risk and duration of endemic coronavirus infections from 2011-2016 with SARS-CoV-2 infections from March 2020-September 2021 in a Nicaraguan pediatric cohort. Respiratory samples were collected from participants that met testing criteria and blood samples were collected annually. Respiratory samples were tested for each of the endemic coronaviruses from 2011-2016 and for SARS-CoV-2 from 2020-2021 via rt-PCR. 2021 blood samples were tested for SARS-CoV-2 antibodies and a subset of 2011-2016 blood samples from four-years-old participants were tested for endemic coronavirus antibodies. By April 2021, 854 (49%) active participants were ELISA positive for SARS-CoV-2 antibodies. Most participants had antibodies against one alpha and one beta coronavirus by age four. We observed 595 symptomatic endemic coronavirus infections from 2011-2016 and 121 symptomatic with SARS-CoV-2 infections from March 2020-September 2021. Symptom presentation of SARS-CoV-2 infection and endemic coronavirus infections were very similar, and SARS-CoV-2 symptomatic infections were as or less severe on average than endemic coronavirus infections. This suggests that, for children, SARS-CoV-2 may be just another endemic coronavirus. However, questions about the impact of variants and the long-term effects of SARS-CoV-2 remain.

Introduction

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transitions to global endemicity, there are many questions about how that will occur. Over time, children will represent the greatest proportion of primary SARS-CoV-2 infections as adults gain immunity from natural infection or vaccination. (1) It is well established that pediatric risk of severe illness and death is much lower than that for adults. (2, 3) Differences in immune response between adults and children likely provide children better protection against severe SARS-CoV-2 infections. (3-5) Previous research found no differences in severity between SARS-CoV-2 infections and influenza A and B among children. (6, 7) However, it is unknown if, in children, SARS-CoV-2 infections are distinct in disease presentation and severity from endemic human coronavirus (HCoV) infections. If SARS-COV-2 infections are more severe, routine pediatric vaccination will be necessary to reduce excess mortality. If not, vaccine-induced immunity should prevent severe disease while allow for transmission to facilitate frequent immune boosting. (1) To determine if SARS-CoV-2 infections have distinct disease presentation from endemic HCoV infections in children, we compare symptomatic SARS-CoV-2 and endemic HCoVs infections symptomology and severity in a prospective, community-based pediatric cohort in Managua, Nicaragua from 2011-2016 and 2020-2021

Methods

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

Institutional review boards at the Nicaraguan Ministry of Health and the University of Michigan approved this study. Parents/guardians of participants provided written informed consent and participants aged >6 years provided verbal assent. The Nicaraguan Pediatric Influenza Cohort Study (NPICS) is a prospective cohort study that began in 2011 and continues today. Participants included in this analysis were members of the NPICS located in District 2 of Managua, Nicaragua between 2011-2016 or March 2020 to September 2021. Children ages 0-14 years who live within the catchment area of Health Center Sócrates Flores Vivas were eligible to participate. Blood samples were collected from each study participant between February and April each year. To confirm our assumption that endemic HCoV infection rates are high in the cohort, we tested a random subset of 100 blood samples from four-year-old's from 2011-2016; using protocols for an enzyme-linked immunosorbent assay (ELISA) developed at Mount Sinai (8), we tested samples for antibody response to the spike protein for each of the four endemic HCoV (alpha: NL63, and 229E, beta: OC43 and HKU1). To confirm that SARS-CoV-2 infections rates were also high, we tested the 2021 blood samples for SARS-CoV-2 antibodies as described previously. (9) Parents/guardians agreed to bring participants to the health center at the first signs of fever. Study personnel collected a respiratory swab from participants if they met the testing criteria: feverishness for participants under two years old; measured fever/feverishness and cough, sore throat, or rhinorrhea; severe respiratory symptoms such as apnea or chest indrawing; hospitalization with respiratory symptoms or sepsis. Testing criteria were expanded in June 2020

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

to capture mild symptomatic SARS-CoV-2 cases; however, this analysis is limited to those meeting the original testing criteria to ensure comparability. We used real-time reverse transcription polymerase-chain reaction (RT-PCR) to test respiratory samples from 2011-2016 for each of the four endemic HCoV, influenza, respiratory syncytial virus (RSV) and human metapneumovirus (HMpV) and samples from March 2020-September 2021 for SARS-CoV-2 and influenza. (10, 11) Study clinicians record all participant symptoms and diagnoses during each clinic visit. Parents/guardians also report participant symptoms at the initial clinic visit, and each day thereafter until symptom resolution. We considered symptoms to be associated with an infection if they occurred within 28 days of symptom onset. Symptoms that were included for follow-up in 2011-2016 and 2020-2021 were feverishness, cough, rhinorrhea, nasal congestion, loss of appetite, myalgia, arthralgia, and rapid breathing. We considered participants who presented to the clinic with rapid breathing, rhonchi, indrawing, wheezing, or shortness of breath as having abnormal breathing. We defined acute lower respiratory infections (ALRI) as physician diagnosed cases of pneumonia, bronchiolitis, bronchitis, or bronchial hyperreactivity. To compare risk of symptoms, we calculated symptom specific risk differences between SARS-CoV-2 infections and endemic HCoV infections, overall and stratified by the following age groups: 0-4, 5-9, and 10-14 years. We also stratified the results by sex and endemic HCoV species. Using upset plots, we explored which signs/symptoms tended to present together. We also assessed symptom duration by comparing the time between each specific symptom onset and the last day participants presented with that symptom. We plotted symptom duration using

boxplots and compared the distribution of symptom duration between SARS-CoV-2 and endemic HCoV using the Mann Whitney U test.

We used SAS version 9.4 (SAS Institute Inc.) to calculate risk differences and ratios and R version 4.1.0 to create figures and conduct all other analyses.

Results

There were 3,220 participants active in NPICS during the included years: 2,576 from 2011-2016 and 1,942 from March 2020-September 2021 with an average of 1,792 per year. Our assumption that detected symptomatic infections consist of only a small proportion of total SARS-CoV-2 and endemic HCoV infections that occurred in the cohort children. Specifically, of the 1,942 children in the cohort from March 2020-September 2021, 1,743 had a blood sample collected in early to mid- 2021 that was tested via ELISA for SARS-CoV-2. 854 (49%) tested positive for SARS-CoV-2 antibodies indicating that SARS-CoV-2 infections were very high in the cohort. We found that 94% of our randomly selected subset of four-year-olds from 2011-2016 had an antibody response to at least one alpha and one beta HCoV, confirming our assumption of high endemic HCoV infection rates in the community. Antibody response prevalence was highest for OC43 (99%) followed by HKU1 (86%), NL63 (83%), and then 229E (74%) (Table 1).

Table 1: Endemic Coronavirus ELISA Results, % Positive

	Total (n=100)
Alpha	94%
NL63	83%
229E	74%
Beta	100%
OC43	99%
HKU1	86%

Within this cohort we observed high infection rates of both endemic HCoVs and SARS-CoV-2. That there were 595 RT-PCR+ symptomatic endemic HCoV infections from 2011-2016 and 121 RT-PCR+ symptomatic SARS-CoV-2 infections from March 2020- September 2021 again suggests that symptomatic cases represent only a small proportion of overall infections. Most endemic HCoV, 432 (73%), and SARS-CoV-2, 59 (49%), infections occurred in participants <5 years. Fever, cough, rhinorrhea, and congestion were the most common symptoms for both endemic HCoVs and SARS-CoV-2 symptomatic infections. Among SARS-CoV-2 symptomatic infections, 4 (3%) were acute lower respiratory infections compared to 98 (16%) endemic HCoV cases (p=<0.0001; Table 2).

Table 2: Study Participants and Symptom Prevalence

	Endemic (n=595)	SARS-CoV-2 (n=121)	p-value
Age Group (%)			<.0001
0-4	432 (73)	59 (49)	
5-9	110 (18)	29 (24)	
10-14	53 (9)	33 (27)	
Symptoms (%)			
Measured Fever	272 (46)	68 (56)	0.035
Cough	524 (88)	85 (70)	< 0.001


			•
Rhinorrhea	505 (85)	93 (77)	0.030
Congestion	276 (46)	45 (37)	0.064
Sore Throat	145 (24)	36 (30)	0.221
Headache	81 (14)	38 (31)	< 0.001
Loss of Appetite	142 (24)	30 (25)	0.828
Diarrhea	64 (11)	14 (12)	0.793
Pneumonia	40 (7)	4 (3)	0.154
Hospitalized	23 (4)	6 (5)	0.578
Abnormal Breathing	108 (18)	8 (6)	0.002
Acute Lower Respiratory Infection	98 (16)	4 (3)	<0.001

^{*} p-value from chi-square test

Across age groups, participants with symptomatic endemic HCoV infections displayed greater risk of cough compared to those with symptomatic SARS-CoV-2 infections. Among participants aged <5 years, symptomatic endemic HCoV infections showed greater risk of rhinorrhea, congestion, abnormal breathing, and ALRI than symptomatic SARS-CoV-2 infections, while SARS-CoV-2 exhibited greater risk of measured fever (Fig 1, Table 3). Notably, symptomatic endemic HCoV infection was associated with greater risk of ALRI even after excluding participants that also tested positive for influenza A, influenza B, RSV, or HMpV. We observed no difference in risk of pneumonia or hospitalization between SARS-CoV-2 and endemic HCoV symptomatic infections. These results were consistent after stratifying by sex (S1-S2 Fig), or endemic HCoV species (S3-S6 Fig).

Fig 1: Symptom Risk Difference between Endemic HCoV and SARS-CoV-2.

150



A: All participants. B: Ages 0-4 years. C: Ages 5-9 years. D Ages: 10-14 years. Positive risk difference indicates higher risk for endemic HCoVs.

Table 3: Symptom Risk Overall and by Age Group

All					
	Endemic (%)	SARS-CoV-2 (%)	Risk Difference (95% CI)	Risk Ratio (95% CI)	
Measured Fever	272 (46)	68 (56)	-0.10 (-0.20, -0.01)	0.81 (0.68, 0.97)	
Cough	524 (88)	85 (70)	0.18 (0.09, 0.26)	1.25 (1.11, 1.41)	
Runny nose	505 (85)	93 (77)	0.08 (-0.00, 0.16)	1.10 (1.00, 1.22)	
Congestion	276 (46)	45 (37)	0.09 (-0.00, 0.19)	1.24 (0.97, 1.60)	
Sore throat	145 (24)	36 (30)	-0.05 (-0.14, 0.03)	0.82 (0.60, 1.11)	
Headache	81 (14)	38 (31)	-0.18 (-0.27, -0.09)	0.43 (0.31, 0.60)	
Loss of appetite	142 (24)	30 (25)	-0.01 (-0.09, 0.07)	0.96 (0.68, 1.35)	
Diarrhea	64 (11)	14 (12)	-0.01 (-0.07, 0.05)	0.93 (0.54, 1.60)	
Pneumonia	40 (7)	4 (3)	0.03 (-0.00, 0.07)	2.03 (0.74, 5.58)	
Hospitalized	23 (4)	6 (5)	-0.01 (-0.05, 0.03)	0.78 (0.32, 1.87)	
Abnormal	100 (10)	0 (7)	0.12 (0.06, 0.17)	2.75 (1.20, 5.40)	
Breathing	108 (18)	8 (7)	0.12 (0.06, 0.17)	2.75 (1.38, 5.48)	
ALRI	98 (16)	4 (3)	0.13 (0.09, 0.18)	4.98 (1.87, 13.28)	
ALRI [†]	77 (15)	4 (3)	0.12 (0.07,0.16)	4.55 (1.70, 12.19)	
	F 1 : (0/)	0-4	D: 1 D: (C) (O70) (CI)	D: 1 D 4: (050/ CI)	
M J. E	Endemic (%)	SARS-CoV-2 (%)	Risk Difference (95% CI)	Risk Ratio (95% CI)	
Measured Fever	218 (50)	44 (75)	-0.24 (-0.36, -0.12)	0.68 (0.57, 0.81)	
Cough	382 (88)	42 (71)	0.17 (0.05, 0.29)	1.24 (1.05, 1.47)	
Runny nose	378 (88)	42 (71)	0.16 (0.04, 0.28)	1.23 (1.04, 1.45)	
Congestion	241 (50)	21 (36)	0.14 (0.09, 0.27)	1.39 (0.97, 1.99)	
Sore throat	66 (15)	6 (10)	0.05 (-0.03, 0.14)	1.50 (0.68, 3.31)	
Headache	23 (5)	4 (7)	-0.01 (-0.08, 0.05)	0.79 (0.28, 2.19)	
Loss of appetite	116 (27)	18 (31)	-0.04 (-0.16, 0.09)	0.88 (0.58, 1.33)	
Diarrhea ·	58 (13)	9 (15)	-0.02 (-0.12, 0.08)	0.88 (0.46. 1.68)	
Pneumonia	38 (9)	3 (5)	0.04 (-0.03, 0.10)	1.73 (0.54, 6.03)	
Hospitalized Abnormal	17 (4)	4 (7)	-0.03 (-0.10, 0.04)	0.58 (0.20, 1.67)	
Breathing	95 (22)	3 (5)	0.17 (0.10, 0.24)	4.34 (1.42, 13.21)	
ALRI	88 (20)	3 (5)	0.15 (0.9, 0.22)	4.00 (1.31, 12.26)	
\mathbf{ALRI}^\dagger	69 (19)	3 (5)	0.13 (0.07,0.20)	3.65 (1.19, 11.21)	
	5-9				
	Endemic (%)	SARS-CoV-2 (%)	Risk Difference (95% CI)	Risk Ratio (95% CI)	
Measured Fever	39 (35)	12 (41)	-0.06 (-0.26, 0.14)	0.86 (0.52, 1.41)	
Cough	99 (90)	21 (72)	0.18 (000, 0.35)	1.24 (0.98, 1.57)	
Runny nose	87 (79)	25 (86)	-0.07 (-0.22, 0.08)	0.92 (0.77, 1.09)	

Congestion	42 (38)	14 (48)	-0.10 (-0.10, 0.30)	0.79 (0.51, 1.23)
Sore throat	52 (47)	12 (41)	0.06 (-0.14, 0.26)	1.14 (0.71, 1.84)
Headache	35 (32)	14 (48)	-0.16 (-0.37, 0.04)	0.66 (0.41, 1.04)
Loss of appetite	19 (17)	7 (24)	-0.07 (-0.24, 0.10)	0.72 (0.33, 1.54)
Diarrhea	4 (4)	3 (10)	-0.07 (-0.18, 0.05)	0.35 (0.08, 1.48)
Pneumonia	2 (2)	1 (3)	-0.02 (-0.9, 0.05)	0.53 (0.05, 5.61)
Hospitalized	5 (5)	2 (7)	-0.02 (-0.12, 0.08)	0.66 (0.13, 3.23)
Abnormal				
Breathing	10 (9)	2 (7)	0.02 (-0.08, 0.12)	1.32 (0.31, 5.69)
ALRI	8 (7)	1 (3)	0.04 (-0.04, 0.12)	2.11 (0.27, 16.19)
ALRI [†]	6 (7)	1 (3)	0.03 (-0.05, 0.11)	1.89 (0.23, 16.93)
10-14				
		10-14		
	Endemic (%)	10-14 SARS-CoV-2 (%)	Risk Difference (95% CI)	Risk Ratio (95% CI)
Measured Fever	Endemic (%) 15 (28)		Risk Difference (95% CI) -0.08 (-0.28, 0.12)	Risk Ratio (95% CI) 0.78 (0.42, 1.45)
Measured Fever	` ′	SARS-CoV-2 (%)	` '	
	15 (28)	SARS-CoV-2 (%) 12 (36)	-0.08 (-0.28, 0.12)	0.78 (0.42, 1.45)
Cough	15 (28) 43 (81)	SARS-CoV-2 (%) 12 (36) 22 (67)	-0.08 (-0.28, 0.12) 0.14 (-0.05, 0.34)	0.78 (0.42, 1.45) 1.22 (0.93, 1.60)
Cough Runny nose	15 (28) 43 (81) 40 (75)	SARS-CoV-2 (%) 12 (36) 22 (67) 26 (79)	-0.08 (-0.28, 0.12) 0.14 (-0.05, 0.34) -0.03 (-0.21, 0.15)	0.78 (0.42, 1.45) 1.22 (0.93, 1.60) 0.96 (0.76, 1.21)
Cough Runny nose Congestion	15 (28) 43 (81) 40 (75) 20 (38)	SARS-CoV-2 (%) 12 (36) 22 (67) 26 (79) 10 (30)	-0.08 (-0.28, 0.12) 0.14 (-0.05, 0.34) -0.03 (-0.21, 0.15) 0.07 (-0.13, 0.28)	0.78 (0.42, 1.45) 1.22 (0.93, 1.60) 0.96 (0.76, 1.21) 1.25 (0.67, 2.32)
Cough Runny nose Congestion Sore throat	15 (28) 43 (81) 40 (75) 20 (38) 27 (51)	SARS-CoV-2 (%) 12 (36) 22 (67) 26 (79) 10 (30) 18 (55)	-0.08 (-0.28, 0.12) 0.14 (-0.05, 0.34) -0.03 (-0.21, 0.15) 0.07 (-0.13, 0.28) -0.04 (-0.25, 0.18)	0.78 (0.42, 1.45) 1.22 (0.93, 1.60) 0.96 (0.76, 1.21) 1.25 (0.67, 2.32) 0.93 (0.62, 1.41)

0

1 (2)

2 (4)

2(4)

Pneumonia

Hospitalized

Abnormal Breathing

ALRI

ALRI[†]

156

157

158

159

160

161

162

For both endemic HCoV and SARS-CoV-2, we found that cough, rhinorrhea, and sore throat frequently presented together. Loss of appetite appeared in common symptom groupings for endemic HCoV, while headache was part of more common groupings for SARS-CoV-2 (Fig 2). We did find that among participants aged 0-4 years decreased appetite lasted longer and

0

3 (9)

0.02 (-0.02, 0.06)

-0.03 (-0.15, 0.08)

0.04 (-0.01, 0.09)

0.04 (-0.01, 0.10)


0.62(0.13, 2.90)

^{*}Positive risk difference, risk ratio > 1 indicates higher risk for endemic HCoV infection.


[†] Excluding influenza A, influenza B, RSV, and HmpV coinfections

- among participants aged 5-9 and 10-14, cough lasted longer for SARS-CoV-2 infections., (Fig 2,
 Supplemental Table 4).
- 166 Fig 2. Comparison of Common Symptom Groupings and Duration between Symptomatic
- 167 Endemic Coronavirus and SARS-CoV-2 Infections.









Feverish Runny_nose Congestion Loss_of_appetite-

10

20

A: Upset plot of symptom groupings for symptomatic SARS-CoV-2 infections. B. Upset plot of symptom groupings for symptomatic endemic coronavirus infections. C. Boxplots of symptom duration

Table 4: Symptom Duration Comparison: SARS-CoV-2, Endemic Coronaviruses

169

170

171

172


Mean Symptom Duration in Days (SD)				
		All		
	SARS-CoV-2	Endemic Coronaviruses	p-value*	
Feverish	3.8 (6.1)	3.8 (7.1)	0.137	
Cough	6.7 (6.4)	5.5 (8.0)	0.003	
Runny nose	4.4 (5.7)	4.6 (7.3)	0.354	
Congestion	2.8 (4.7)	2.8 (5.6)	0.997	
Decreased appetite	2.2 (2.8)	1.4 (3.4)	0.032	
	0-	4	•	
	SARS-CoV-2	Endemic Coronaviruses	p-value*	
Feverish	5.2 (7.3)	4.4 (7.6)	0.069	
Cough	6.4 (6.0)	6.4 (8.6)	0.178	
Runny nose	5.1 (5.8)	5.4 (7.8)	0.278	
Congestion	2.6 (3.8)	3.0 (5.8)	0.875	
Decreased appetite	2.5 (2.9)	1.6 (3.7)	0.039	
	5-	.9	•	
	SARS-CoV-2	Endemic Coronaviruses	p-value*	
Feverish	2.0 (4.0)	2.4 (5.4)	0.397	
Cough	8.1 (7.5)	3.2 (5.8)	0.002	
Runny nose	3.9 (5.5)	2.3 (4.7)	0.125	
Congestion	3.4 (6.3)	1.9 (4.4)	0.690	
Decreased appetite	2.1 (26)	1.0 (1.2)	0.351	
10-14				
	SARS-CoV-2	Endemic Coronaviruses	p-value*	
Feverish	2.6 (4.7)	1.7 (3.8)	0.434	
Cough	6.0 (6.2)	2.3 (4.3)	0.015	
Runny nose	3.5 (6.0)	2.2 (5.0)	0.440	
Congestion	2.5 (3.9)	2.6 (5.6)	0.479	
Decreased appetite	1.2 (2.2)	0.4 (0.8)	0.698	

*From Mann-Whitney U test


To assess the potential impact of variants on symptoms, we compared symptoms for SARS-CoV-2 infections from 2020 prior to the global emergence of variants and 2021 when delta, gamma, and lambda strains circulated in the cohort area and found no difference in presentation by year (Fig 3). All observed cases of ALRI associated with SARS-CoV-2 occurred in 2020. However, we did find that rhinorrhea lasted longer in SARS-CoV-2 cases from 2021 compared to 2020 (Table 5).

- Fig 3. Comparison of Common Symptom Groupings between Symptomatic SARS-CoV-2
- **Infections in 2020 and 2021**





В



A: 2020. B. 2021

Table 5: Symptom Duration Comparison: SARS-CoV-2 by Year

	Mean Symptom Duration in Days (SD)		p-value*
	2020	2021	_
Feverish	4.1 (7.4)	3.46(5.0)	0.129
Cough	6.8 (8.0)	6.7 (5.5)	0.378
Runny nose	2.7 (5.0)	5.4 (6.0)	0.004
Congestion	1.6 (2.3)	3.3 (5.2)	0.382
Decreased appetite	3.5 (3.8)	1.6 (1.9)	0.172

^{*}From Mann-Whitney U test

Discussion

This is, to our knowledge, the first study that assesses differences in symptom presentation, duration, and severity between SARS-CoV-2 and endemic HCoV symptomatic infections among children. Understanding how SARS-CoV-2 infections compare to endemic HCoV infections is important as SARS-CoV-2 becomes endemic. While our study does not evaluate asymptomatic or very mild illness, we provide comparisons of medically attended illness associated with endemic HCoV and SARS-CoV-2 symptomatic infections in a large cohort of children with high infection rates.

In this pediatric cohort, we found that with 854 (49%) participants tested positive for SARS-CoV-2 antibodies in 2021 with only 121 PCR confirmed infections that met the original testing criteria, like results from our community-based household cohort study. (9) We also found that most participants had at least one alpha and one beta HCoV infection by age four

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

level.

suggesting that in this cohort, participants have had at least two endemic HCoV exposures by the age of four. This is similar to previous studies that showed that by age six, most children have had infections with each of the four endemic HCoVs with a majority being asymptomatic infections. (12) Thus for SARS-CoV-2 and endemic HCoV, symptomatic infections also represent only a small proportion of all pediatric infections.

Comparing these symptomatic infections, we found that, overall, disease presentation is very similar between endemic HCoV and SARS-CoV-2, with each frequently presenting with "common cold" symptoms. Consistent with other studies, we found differences in symptom presentation by age perhaps in part because older children have had more endemic HCoV exposures (2, 4, 13). We also found great variability in symptom duration for SARS-CoV-2 and endemic HCoV infections with symptoms lasting from 1-28 days or more. (14) There was a difference in duration of decreased appetite for the youngest participants and cough for those aged 5-14 years suggesting that some symptoms may last longer for SARS-CoV-2 infections. We also found a difference in rhinorrhea duration between SARS-CoV-2 infections in 2020 and 2021, suggesting that SARS-CoV-2 variants may increase symptom duration among children. Across age groups, risk of ALRI associated with SARS-CoV-2 was the same or lower compared to ALRI associated with endemic HCoV infection. Even when excluding endemic HCoV co-infections with pathogens commonly associated with ALRI, the conclusions did not change. These results show that, for children, the risk of ALRI and severe illness from SARS-CoV-2 infections is comparable to the risk from endemic HCoV infections at the community

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

The main strength of this community-based study is its size and duration. Consistent viral surveillance and symptom evaluation within the same population allow for year-to-year comparisons and facilitates our comparisons of endemic HCoV and SARS-CoV-2. The high number of participants under the age of five (about 36% of participants during these years), allows us to evaluate SARS-CoV-2 in an age group with little representation in current literature. Additionally, this cohort was already well established when SARS-CoV-2 began circulating in Nicaragua allowing us to quickly incorporate questions regarding its effects on this population. However, this study does have some limitations. First, using data from this communitybased cohort study we were not powered to detect the most severe manifestations of SARS-CoV-2 including death or Multisystem Inflammatory Syndrome in Children (MIS-C) and other rare outcomes. (15, 16) Second, our analysis did not include genetic sequencing preventing us from assessing the importance of variants in presentation and severity of SARS-CoV-2 illness. We did compare SARS-CoV-2 symptom presentation, severity, and duration by year and found little or no difference. Finally, while our study does not evaluate asymptomatic illness for endemic HCoVs, our results were consistent with other research, showing that childhood HCoVs are ubiquitous and that symptomatic cases represent only a small proportion of infections, as with SARS-CoV-2. (12) In this study, we observed that symptomatic SARS-CoV-2 infections at the community level are very similar to symptomatic endemic HCoV infections in symptom presentation. Among children in a setting with a high SARS-CoV-2 infection rate, symptomatic SARS-CoV-2 infections are on average as or less severe as endemic HCoV infections. These findings support

the hypothesis that SARS-CoV-2 may be like another endemic HCoV for children—most children will be asymptomatic with rare cases of severe symptomatic illness. This does not mean SARS-CoV-2 in children is not important. There are many unknowns about the long-term effects and impact of repeat infections among children. (1) Increased transmissibility of emerging variants is also a cause for concern, as it will lead to increased frequency of severe manifestations. Future mutations in the virus needed to be monitored as they may also increase illness severity in children. Despite relatively low risk of severe illness among children, pediatric vaccination that mirrors natural induced immunity against SARS-CoV-2 would further lower individual risk and reduce the number of severe cases and deaths due to SARS-CoV-2.

References

243

244

245

246

247

248

249

250

251

252

- Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of
- 255 COVID-19 to endemicity. Science. 2021;371(6530):741-5.
- 256 2. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among
- 257 Children in China. Pediatrics. 2020;145(6).
- 258 3. Do LAH, Anderson J, Mulholland EK, Licciardi PV. Can data from paediatric cohorts
- 259 solve the COVID-19 puzzle? PLoS Pathog. 2020;16(9):e1008798.
- 260 4. Dhochak N, Singhal T, Kabra SK, Lodha R. Pathophysiology of COVID-19: Why
- 261 Children Fare Better than Adults? Indian J Pediatr. 2020;87(7):537-46.
- 262 5. Khan T, Rahman M, Ali FA, Huang SSY, Ata M, Zhang Q, et al. Distinct antibody
- repertoires against endemic human coronaviruses in children and adults. JCI Insight. 2021;6(4).

- 264 6. Siddiqui M, Gultekingil A, Bakirci O, Uslu N, Baskin E. Comparison of clinical features
- and laboratory findings of coronavirus disease 2019 and influenza A and B infections in
- 266 children: a single-center study. Clin Exp Pediatr. 2021.
- 267 7. Pokorska-Spiewak M, Talarek E, Popielska J, Nowicka K, Oldakowska A, Zawadka K, et
- al. Comparison of clinical severity and epidemiological spectrum between coronavirus disease
- 269 2019 and influenza in children. Sci Rep. 2021;11(1):5760.
- 270 8. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al.
- 271 SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen
- 272 Production, and Test Setup. Curr Protoc Microbiol. 2020;57(1):e100.
- 9. Maier HE, Kuan G, Saborio S, Bustos Carrillo FA, Plazaola M, Barilla C, et al. Clinical
- spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection. Clin Infect
- 275 Dis. 2021.
- 276 10. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, et al. Molecular Diagnosis
- of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clin Chem.
- 278 2020;66(4):549-55.
- 279 11. Real-Time RT-PCR Assays for Non-Influenza Respiratory Viruses. In: Diseases NCfIaR,
- 280 editor.: Centers for Disease Control and Prevention; 2015. p. 1-16.
- 281 12. Zhou W, Wang W, Wang H, Lu R, Tan W. First infection by all four non-severe acute
- respiratory syndrome human coronaviruses takes place during childhood. BMC Infect Dis.
- 283 2013;13:433.


284 13. Ogimi C, Kim YJ, Martin ET, Huh HJ, Chiu CH, Englund JA. What's New With the Old 285 Coronaviruses? J Pediatric Infect Dis Soc. 2020;9(2):210-7. 286 14. Molteni E, Sudre CH, Canas LS, Bhopal SS, Hughes RC, Antonelli M, et al. Illness 287 duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. 288 Lancet Child Adolesc Health. 2021. 289 15. Children and COVID-19: State-Level Data Report. American Academy of Pediatrics 290 2021 August 12, 2021. 291 Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, et al. 16. 292 Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected 293 With SARS-CoV-2. JAMA Netw Open. 2021;4(6):e2116420. 294 **Supporting information** 295 296 297 298 299 300 301

S1 Fig. Symptom Risk Difference between Endemic HCoVs and SARS-CoV-2 for Females.

302

304

305




A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14. Positive risk difference indicates higher risk for endemic HCoV infection

S2 Fig. Symptom Risk Difference between Endemic HCoVs and SARS-CoV-2 for Males.

307

309

310



A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14. Positive risk difference indicates higher risk for endemic HCoV infection


S3 Fig. Symptom Risk Difference NL63 and SARS-CoV-2.

312

314

315

316



A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14. Positive risk difference indicates


higher risk for endemic HCoV infection

S4 Fig. Symptom Risk Difference between 229E and SARS-CoV-2.

317

319

320




A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14. Positive risk difference indicates higher risk for endemic HCoV infection

S5 Fig. Symptom Risk Difference between OC43 and SARS-CoV-2.

322

324

325




A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14. Positive risk difference indicates higher risk for endemic HCoV infection

S6 Fig. Symptom Risk Difference between HKU1 and SARS-CoV-2.

327

329

330



A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14. Positive risk difference indicates

higher risk for endemic HCoV infection